These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28263465)

  • 1. Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.
    Bednasz CJ; Venuto CS; Ma Q; Morse GD
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):135-139. PubMed ID: 28263465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
    Meemken L; Hanhoff N; Tseng A; Christensen S; Gillessen A
    Ann Pharmacother; 2015 Jul; 49(7):796-807. PubMed ID: 25902733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
    Burgess S; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
    Ann Pharmacother; 2015 Jun; 49(6):674-87. PubMed ID: 25770114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.
    Ogbuagu O; Friedland G; Bruce RD
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):721-31. PubMed ID: 27140427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person.
    El-Sherif O; Back D
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):336-43. PubMed ID: 26159742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents.
    McCance-Katz EF
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S89-95. PubMed ID: 16265622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
    Bruce RD; Moody DE; Altice FL; Gourevitch MN; Friedland GH
    Expert Rev Clin Pharmacol; 2013 May; 6(3):249-69. PubMed ID: 23656339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.
    Karageorgopoulos DE; El-Sherif O; Bhagani S; Khoo SH
    Curr Opin Infect Dis; 2014 Feb; 27(1):36-45. PubMed ID: 24305043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.
    Milazzo L; Cattaneo D; Calvi E; Gervasoni C; Mazzali C; Ronzi P; Peri AM; Ridolfo AL; D'Avolio A; Antinori S
    Int J Antimicrob Agents; 2015 May; 45(5):545-9. PubMed ID: 25769784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
    Rodríguez-Torres M
    Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment options for hepatitis C patients co-infected with HIV.
    Rockstroh JK; Hardy WD
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):689-95. PubMed ID: 26799571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications.
    Smolders EJ; de Kanter CT; de Knegt RJ; van der Valk M; Drenth JP; Burger DM
    Clin Pharmacokinet; 2016 Dec; 55(12):1471-1494. PubMed ID: 27317413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of acute and chronic HCV infection in persons with HIV coinfection.
    Sulkowski MS
    J Hepatol; 2014 Nov; 61(1 Suppl):S108-19. PubMed ID: 25443339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral and anti-hepatitis C virus direct-acting antiviral-related hepatotoxicity.
    Han H; Agarwal R; Martel-Laferriere V; Dieterich DT
    Clin Liver Dis; 2013 Nov; 17(4):657-70, ix. PubMed ID: 24099023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Risk Management and Hepatitis C: Combining Drugs.
    Smolders EJ; Ter Horst PJG; Wolters S; Burger DM
    Clin Pharmacokinet; 2019 May; 58(5):565-592. PubMed ID: 30259390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
    Seden K; Back D; Khoo S
    J Antimicrob Chemother; 2010 Jun; 65(6):1079-85. PubMed ID: 20335191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.
    Jafari A; Khalili H; Izadpanah M; Dashti-Khavidaki S
    Expert Opin Drug Saf; 2015 May; 14(5):713-31. PubMed ID: 25813487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.